Stock VICO VICORE PHARMA HOLDING AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Vicore Pharma Holding AB

Equities

VICO

SE0007577895

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:39 2024-04-26 am EDT 		5-day change 1st Jan Change
17.3 SEK +3.72% Intraday chart for Vicore Pharma Holding AB +6.00% +22.00%
Apr. 04 Vicore Pharma Holding AB Announces Maarten Kraan, as Board Member Declined Re-Election CI
Mar. 19 Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 737.6 1,903 998.9 1,465 1,584 1,933 - -
Enterprise Value (EV) 1 550 1,655 704.7 1,203 1,251 1,659 1,711 1,761
P/E ratio -6.81 x -11.6 x -3.28 x -4.49 x -4.4 x -12.8 x -7.74 x -7.99 x
Yield - - - - - - - -
Capitalization / Revenue - - - - - 18.6 x 4.92 x 258 x
EV / Revenue - - - - - 16 x 4.35 x 235 x
EV / EBITDA -5.93 x -11.1 x -2.42 x -4.19 x -4.89 x -11.1 x -10.3 x -5.81 x
EV / FCF -3.35 x -13.3 x -2.59 x -5.33 x -3.17 x -37.7 x -5.59 x -5.64 x
FCF Yield -29.8% -7.51% -38.6% -18.8% -31.5% -2.65% -17.9% -17.7%
Price to Book - 5.37 x 2.61 x 5.07 x 3.01 x 6.55 x 11 x 25.4 x
Nbr of stocks (in thousands) 50,175 60,418 71,760 81,848 111,723 111,723 - -
Reference price 2 14.70 31.50 13.92 17.90 14.18 17.30 17.30 17.30
Announcement Date 2/28/20 2/26/21 2/25/22 2/28/23 2/28/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - 104 393.1 7.5
EBITDA 1 -92.68 -149.5 -291.2 -287.1 -255.5 -149.4 -166.3 -303.4
EBIT 1 -94.01 -149.5 -294.8 -290.7 -321.5 -151.1 -167 -303.4
Operating Margin - - - - - -145.25% -42.48% -4,044.91%
Earnings before Tax (EBT) 1 -93.33 -147.3 -296.7 -288.8 -311.3 -151.1 -166.1 -302.4
Net income 1 -93.08 -146.9 -296.5 -288.4 -310.9 -151.1 -165.9 -302.2
Net margin - - - - - -145.25% -42.2% -4,029.63%
EPS 2 -2.160 -2.710 -4.250 -3.990 -3.220 -1.352 -2.236 -2.165
Free Cash Flow 1 -164.1 -124.3 -272.2 -225.9 -394 -44 -306 -312
FCF margin - - - - - -42.31% -77.83% -4,160%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 2/28/20 2/26/21 2/25/22 2/28/23 2/28/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q2 2023 Q1 2023 Q2 2023 Q3 2023 Q4
Net sales - - - - - - -
EBITDA 1 - - -63.95 -65.18 -68.96 -64.22 -69.17
EBIT 1 - - -64.9 -66.1 -69.8 -65.06 -120.6
Operating Margin - - - - - - -
Earnings before Tax (EBT) 1 -97.67 -80.29 - -66.38 -69.3 -63.66 -112
Net income 1 -97.55 -80.4 -65.9 -66.3 -69.2 -63.56 -111.9
Net margin - - - - - - -
EPS 2 -1.360 -1.120 - -0.8100 -0.8500 -0.5800 -1.000
Dividend per Share 2 - - - - - - -
Announcement Date 11/4/21 2/25/22 8/25/22 5/4/23 8/24/23 11/2/23 2/28/24
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 188 249 294 262 334 274 222 172
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -164 -124 -272 -226 -394 -44 -306 -312
ROE (net income / shareholders' equity) -30.7% -43.4% -80.4% -85.8% -83.5% -39.7% -76.1% -120%
ROA (Net income/ Total Assets) -29% -39.3% -69.1% -73% -74.5% -25.3% -107% -104%
Assets 1 321.4 373.9 428.9 394.8 417.1 597.1 154.5 290.9
Book Value Per Share 2 - 5.870 5.340 3.530 4.720 2.640 1.570 0.6800
Cash Flow per Share - - - - - - - -
Capex 1 - - - - - - - -
Capex / Sales - - - - - - - -
Announcement Date 2/28/20 2/26/21 2/25/22 2/28/23 2/28/24 - - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
17.3 SEK
Average target price
61.5 SEK
Spread / Average Target
+255.49%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VICORE PHARMA HOLDING AB Stock Vicore Pharma Holding AB
+22.00% 176M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. VICO Stock
  4. Financials Vicore Pharma Holding AB